

EXPRESS MAIL NO.: EL 501 636 636 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Busfield et al.

Application No.: 09/503,387

Group Art Unit: 1656

Filed: February 14, 2000

Examiner: Strzelecka, T.

For: GLYCOPROTEIN VI AND USES  
THEREOF

Attorney Docket No.: 7853-178

**PRELIMINARY AMENDMENT AND  
RESPONSE TO RESTRICTION REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 25 2001

TECH CENTER 1600/2900

Sir:

In response to the Restriction Requirement, mailed December 29, 2000, and in accordance with Rule 142 of the Rules of Practice, please enter the amendments and consider the remarks below. Applicants submit herewith: (1) a copy of the pending claims, attached hereto as Exhibit A; (2) an Amendment Fee Transmittal, accompanied by the appropriate provision for payment of the required fee; (3) an Information Disclosure Statement Under 37 C.F.R. § 1.56 and § 1.97; and (4) a revised PTO form 1449.

It is estimated that no fee is necessary for filing this response. In the event a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

**IN THE CLAIMS:**

Please amend the claims, as follows:

Cancel Claims 1-23, without prejudice.

Add new Claims 24-70, as follows:

--24. (new) A composition of substantially purified antibodies, or fragments thereof, which antibodies specifically bind to a polypeptide comprising an amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the